

SCI PHARMTECH, INC. 旭富製藥科技

簡報

ISO 14001

BUREAU VERITAS
Certification



ISO 9001

BUREAU VERITAS
Certification



公司概況Profile



員工數Employee : 213

設立日期：中華民國七十六年九月十八日

Date of establishment: Sep. 18, 1987

資本額Capital：新台幣697佰萬元(NTD 697mn)

營業項目Business：

原料藥API (55.06%)

中間體Intermediate (37.67%)

特用化學品 Custom-made chemicals (7.27%)

公司概況 Outline

	Y2014	Y2015
歐洲 Europe	42.65%	38.78%
美洲 America	21.70%	25.07%
亞洲 Asia	18.18%	21.24%
國內 Taiwan	16.63%	9.46%
其他 others	0.84%	5.45%
合計 Total	100.00%	100.00%

製藥產業的上、中、下游 SCI's position

上游
Upstream

基本原料 RM



中間體 Intermediate:

生產原料藥之
中間步驟所產出之產品 Products before API



中游
Midstream

原料藥 API:

製劑中之有效成分 Treatable ingredient



下游

Downstream

製劑: 成品藥 Formulation

旭富營業範圍

SCI's businesses

營運概況-IS

Unit: K NTD

	2014	2015 to date
營收Sales	1,491,862	443,065
營業成本COGS	(1,012,509)	(273,443)
毛利Gross Profit	479,353	169,622
毛利率 GP Ratio	32.1%	38.3%
營業費用Operating Expenses	(183,987)	(53,885)
營業利益Operating Income	295,366	115,737
營業外損益Non-Operating In/Ex	39,728	(2,070)
稅前淨利 Net Profit before Tax	335,094	113,667
所得稅Income Tax	(70,255)	(20,849)
本期淨利Net Profit after Tax	264,839	92,818


產品組合-Products

Y2012	%		Y2013	%		Y2014	%
V.A.	18.66%		PGA	18.31%		PGA	17.49%
PGA	16.61%		Di-VaNa	16.92%		Di-VANa	10.09%
Di-VaNa	15.97%		S20/38	8.39%		LPF.Na	8.74%
PPON	7.88%		V.A.	8.23%		S20/38	8.25%
Pent-2	4.78%		LPF.Na	6.58%		V.A.	8.15%
5-HMT	4.33%		PPON	6.53%		DBS	4.60%
M85	3.89%		5-HMT	4.51%		5-HMT	4.12%
DBS	2.73%		PEB.Na	3.98%		NaVA	3.65%
M115	2.59%		NaVa	3.34%		Pent-2	3.64%
M74	2.18%		DBS	2.63%		T115	3.33%
Total	79.62%		Total	79.42%		Total	72.06%

No.	Product	%	2015 Sales (NT\$)
1	HOCLQ Sulfate	17.86%	111,607,197
2	PGA	14.97%	93,554,618
3	LPF.Na	13.29%	83,015,044
4	V.A.	9.07%	56,643,217
5	Di-VANa	8.68%	54,223,784
6	DBS	5.46%	34,113,986
7	Pent-2	4.33%	27,047,292
8	S-MMAA	3.49%	21,815,500
9	T-115	3.22%	20,143,000
10	3-Azetidinol.HCl	2.06%	12,899,411

產品介紹Product

● Pyrogallolaldehyde (PGA) - Benserazide



✓ 治療帕金森氏症之中間體

Intermediate for Parkinson's Disease


✓ 2個客戶

2 customers

✓ 2015 sales: 94M

產品介紹Product

● Divalproex Sodium (Di-Va)




- ✓ 學名藥於2009推出
- ✓ 10個客戶
- ✓ 2015 sales: 54M

Generic came out in 2009
10 customers


產品介紹Product

Anti-inflammatory (Loxoprofen sodium)



日本市場200-300公噸
Japan market: 200-300MT
2015 sales: 83M

S20/38



臨床藥物
Medication in clinical trial

產品介紹Product

Valproic Acid (VA)




✓ 20個客戶

20 customers

✓ 2015 sales: 57M


產品介紹Product

Sodium Valproate (NaVA)



- ✓ 24 客戶 24 customers
- ✓ 2015 sales: 12M


5-HMT – Ritonavir, Lopinavir



- ✓ 愛滋病藥物中間體
For AIDS treatment
- ✓ 2015 sales: 8M


產品介紹Product

Pentobarbital Sodium (鎮定安眠用, calmative)



2015 sales:12M

Pent-2



2015 sales:27M

產品介紹Product

Antidepressant (Duloxetine)

- ✓ 2013年底專利到期 Patent expired in the end of 2013
- ✓ 2014 sales: 12 M
- ✓ 2015 sales: 3M

Antidepressant (S-MMAA)

- ✓ Duloxetine之中間體 intermediate of Duloxetine
- ✓ 2014 sales: 27 M
- ✓ 2015 sales: 22 M

產品介紹Product

Hydroxychloroquine sulfate

- ✓ 風濕性關節炎藥物 For rheumatoid arthritis
- ✓ 4個客戶 4 customers
- ✓ 2015sales: 112M

GMP Status(GMP現況)

<i>API</i>	<i>CGMP certified (TFDA)</i>	<i>CEP (EDQM)</i>	<i>DMF (USA)</i>	<i>MF (Japan)</i>	<i>DMF (Canada)</i>
Valproic Acid (*)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011		
Probucol	2004		2004		
Sodium Valproate	2004	2006			
Divalproex Sodium (**)	2005		2005		2010
Bisoprolol Fumarate	2006				
Pentobarbital Sodium	2009	2011			
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2011	2014			
Duloxetine Hydrochloride	2012	2014	2010/2011		
Thiopental acid	2012				
Loxoprofen Sodium Hydrate	2012			2011	
Articaine Hydrochloride	2013	2014			
Hydroxychloroquine Sulfate	2014		2014		
Clindamycin Palmitate HCl			2011		
Cyclophosphamide			2012		

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010

簡報完畢



敬請指教